In this article by the Medicine Maker, Richard Castledine discusses how to identify a safe, cost-efficient, and sustainable route to scalable API synthesis.
The article explores the complexities of developing Active Pharmaceutical Ingredients (APIs) and offers strategies to optimize their synthesis. Balancing the need for quality with the speed of development is crucial during the transition from candidate selection to first-in-human clinical trials. Deploying data-driven API development strategies early in a drug program can mitigate downstream development risks.
Continue reading the article on Medicine Maker.